Atypical Hemolytic Uremic Syndrome
This is a registry. The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.
- Male or female patients of any age, including minors, who have been diagnosed with aHUS
- Able to give written informed consent. Patient or patient's parent/legal guardian must be willing and able to given written informed consent and the patient (if minor) must be willing to give written informed assent [if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)].
- ADAMTS13 > 5%, if performed.
- Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin
Principal Investigator Name
Sharon Su, MD
Last Updated: Friday, August 23, 2013 02:49:19 PM